Cargando…

Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension

PRECIS: In pooled phase III analyses, once-daily netarsudil 0.02% resulted in intraocular pressure (IOP) reduction that was noninferior to twice-daily timolol 0.5%, with minimal treatment-related serious or systemic adverse events (AEs). Ocular AEs were generally tolerable. PURPOSE: The purpose of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Inder P., Fechtner, Robert D., Myers, Jonathan S., Kim, Terry, Usner, Dale W., McKee, Hayley, Sheng, Huan, Lewis, Richard A., Heah, Theresa, Kopczynski, Casey C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647436/ https://www.ncbi.nlm.nih.gov/pubmed/32826769 http://dx.doi.org/10.1097/IJG.0000000000001634

Ejemplares similares

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
por: Asrani, Sanjay, et al.
Publicado: (2020)

A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma
por: Peace, James H., et al.
Publicado: (2020)

Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
por: Araie, Makoto, et al.
Publicado: (2021)

The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
por: Kazemi, Arash, et al.
Publicado: (2018)

Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
por: Fridman, Gabrielle, et al.
Publicado: (2021)

Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
por: Lin, Cheng-Wen, et al.
Publicado: (2018)

A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension
por: Wang, Tao, et al.
Publicado: (2022)

Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
por: Dasso, Lily, et al.
Publicado: (2018)

Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)
por: Araie, Makoto, et al.
Publicado: (2023)

Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
por: Ren, Ruiyi, et al.
Publicado: (2016)

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study
por: Walters, Thomas R., et al.
Publicado: (2022)

Effects of Netarsudil on Actin-Driven Cellular Functions in Normal and Glaucomatous Trabecular Meshwork Cells: A Live Imaging Study
por: Keller, Kate E., et al.
Publicado: (2020)

Netarsudil-Induced Corneal Flattening in a Child with Secondary Open-Angle Glaucoma
por: Ganesh, Durga, et al.
Publicado: (2022)

Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety
por: Mathur, Manoj Chandra, et al.
Publicado: (2023)

Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
por: Wisely, C. Ellis, et al.
Publicado: (2020)

Netarsudil-associated epithelial keratopathy
por: Ramakrishnan, Meera S., et al.
Publicado: (2020)

Effectiveness of Netarsudil as an Additional Therapy for Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
por: Villegas, Natacha C, et al.
Publicado: (2021)

Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial
por: Wang, Ming, et al.
Publicado: (2023)

Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials
por: Luo, Nachuan, et al.
Publicado: (2022)

Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system
por: Ryan, Gerard, et al.
Publicado: (2011)

Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients
por: Koh, Kyungmin, et al.
Publicado: (2021)

PW02-002 - Single MVK mutation and recurrent fevers
por: Barron, K, et al.
Publicado: (2013)

Netarsudil-associated reticular corneal epithelial edema
por: Tran, Jennifer A., et al.
Publicado: (2022)

Reticular corneal epithelial edema with topical netarsudil
por: Parmar, Dipali P., et al.
Publicado: (2023)

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
por: Shiratori, Naka, et al.
Publicado: (2021)

Effect of Current Density on the Corrosion Resistance and Photocatalytic Properties of Cu-Ni-Zn(0.96)Ni(0.02)Cu(0.02)O Nanocomposite Coatings
por: Tan, Haifeng, et al.
Publicado: (2023)

Effectiveness of Netarsudil versus Brimonidine in Eyes already Being Treated with Glaucoma Medications at a Single Academic Tertiary Care Practice: A Comparative Study
por: Pham, Alex T., et al.
Publicado: (2022)

P02-002 - IL36RN mutations in patients with DITRA
por: Arostegui, JI, et al.
Publicado: (2013)

Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension
por: Iester, Michele
Publicado: (2008)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Ocular perfusion pressure and ophthalmic artery flow in patients with normal tension glaucoma
por: Samsudin, Amir, et al.
Publicado: (2016)

Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension
por: Fingeret, Murray, et al.
Publicado: (2019)

OR3-002 – Blau Syndrome cohort study: ocular outcome
por: Rose, CD, et al.
Publicado: (2013)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
por: Walimbe, Tejaswini, et al.
Publicado: (2016)

Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension
por: Sharma, Sourabh, et al.
Publicado: (2015)

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
por: Olander, Kenneth W., et al.
Publicado: (2021)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee, Daniel, et al.
Publicado: (2017)

“Rapid and reversible alteration in corneal contour and power associated with Netarsudil/Latanoprost”
por: Chung, David, et al.
Publicado: (2022)

Two pediatric cases of reticular corneal epithelial edema associated with netarsudil
por: Guzman Aparicio, Maria A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kof9ngcofu5baf6ahpqjaratf3